Q&A With Mark Freedman From the University Ottawa: Longterm Studies of Aubagio Continue to Show Safety for Multiple Sclerosis Treatment

With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.

Mark Freedman, HBSc, MSc, MD, CSPQ, from the University of Ottawa addressed the recent work on the treatment during ECTRIMS 2015 in Barcelona. Freedman noted that Aubagio has the distinction of being the only oral treatment for multiple sclerosis to not have any "major" safety issues present during its time.